Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

References

• LièvreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res2006663992399516618717
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163418316791
   PubMed Web of Science ®Google Scholar
• McShaneLMHayesDFPublication of tumor marker research results: the necessity for complete and transparent reportingJ Clin Oncol2012304223423223071235
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJKRAS mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176518946061
   PubMed Web of Science ®Google Scholar
• AndreyevHJNormanARCunninghamDKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBr J Cancer20018569269611531254
   PubMed Web of Science ®Google Scholar
• RothADTejparSDelorenziMPrognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 TrialJ Clin Oncol20102846647420008640
   PubMed Web of Science ®Google Scholar
• SaridakiZPapadatos-PastosDTzardiMBRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcomeBr J Cancer20101021762176820485284
   PubMed Web of Science ®Google Scholar
• SouglakosJPhilipsJWangRPrognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerBr J Cancer200910146547219603024
   PubMed Web of Science ®Google Scholar
• TolJNagtegaalIDPuntCJBRAF mutation in metastatic colorectal cancerN Engl J Med2009361989919571295
   PubMed Web of Science ®Google Scholar
• SamowitzWSSweeneyCHerrickJPoor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancersCancer Res2005656063606916024606
   PubMed Web of Science ®Google Scholar
• DownwardJTargeting RAS signalling pathways in cancer therapyNat Rev Cancer20033112212509763
   PubMed Web of Science ®Google Scholar
• SchubbertSShannonKBollagGHyperactive Ras in developmental disorders and cancerNat Rev Cancer2007729530817384584
   PubMed Web of Science ®Google Scholar
• MalumbresMBarbacidMRAS oncogenes: the first 30 yearsNat Rev Cancer2003345946512778136
   PubMed Web of Science ®Google Scholar
• BosJLRas oncogenes in human cancer: a reviewCancer Res198949468246892547513
   PubMed Web of Science ®Google Scholar
• RakJYuJLKerbelRSCoomberBLWhat do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?Cancer Res2002621931193411929804
   PubMed Web of Science ®Google Scholar
• MizukamiYKohgoYChungDCHypoxia inducible factor-1 independent pathways in tumor angiogenesisClin Cancer Res20026219311934
   Google Scholar
• KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with MCRCJ Clin Oncol200321606512506171
   PubMed Web of Science ®Google Scholar
• KabbinavarFFSchulzJMcCleodMAddition of bevacizumab to bolus fluorouracil and leucoverin in first-line metastatic colorectal cancer: results of a randomized phase II trialJ Clin Oncol2005233697370415738537
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovontnyWBevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJNealJBevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol2007251539154417442997
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol2008262013201918421054
   PubMed Web of Science ®Google Scholar
• WongRCunninghamDBarbachanoYA multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for up-front resectionAnn Oncol2011222042204821285134
   PubMed Web of Science ®Google Scholar
• Díaz-RubioEGómez-EspañaAMassutíBFirst-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD studyOncologist201217152522234633
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDContinuation of bevacizumab after progression in metastatic colorectal cancer (ML18147): a randomized phase III trialLancet Oncol201314293723168366
   PubMed Web of Science ®Google Scholar
• TieJLiptonLDesaiJKRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancerClin Cancer Res2011171122113021239505
   PubMed Web of Science ®Google Scholar
• RossiLVeltriEZulloABevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practiceFuture Oncol201281193119723030493
   PubMed Web of Science ®Google Scholar
• SangerFNicklenFCoulsonARDNA sequencing with chain-terminating inhibitorsProc Natl Acad Sci U S A19777454635467271968
   PubMed Web of Science ®Google Scholar
• TournigandCAndréTAchilleEFOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol20042222923714657227
   PubMed Web of Science ®Google Scholar
• ColucciGGebbiaVPaolettiGPhase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia MeridionaleJ Clin Oncol2005234866487515939922
   PubMed Web of Science ®Google Scholar
• BendellJCBekaii-SaabTSCohnALTreatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyOncologist2012171486149523015662
   PubMed Web of Science ®Google Scholar
• ModestDPStintzingSLaubenderRPClinical characterization of patients with metastatic colorectal cancer depending on the KRAS statusAnticancer Drugs20112291391821795973
   PubMed Web of Science ®Google Scholar
• NashGMGimbelMShiaJKRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastasesAnn Surg Oncol20101757257819727962
   PubMed Web of Science ®Google Scholar
• InceWLJubbAMHoldenSNAssociation of KRAS, b-raf, and p53 status with the treatment effect of bevacizumabJ Natl Cancer Inst20059798198915998951
   PubMed Web of Science ®Google Scholar
• HurwitzHIYiJInceWNovotnyWFRosenOThe clinical benefit of bevacizumab in metastatic colorectal cancer is independent of KRAS mutation status: analysis of phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancerOncologist200914222819144677
   PubMed Web of Science ®Google Scholar
• Díaz-RubioEGómez-EspañaAMassutíBRole of KRAS status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative studyPLoS One20127e4734523174912
   PubMed Web of Science ®Google Scholar
• MasiGLoupakisFSalvatoreLBevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialLancet Oncol20111184585220702138
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab and cetuximab in metastatic colorectal cancerN Engl J Med200936056357019196673
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol20092767268019114685
   PubMed Web of Science ®Google Scholar
• PriceTJHardinghamJELeeCKImpact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancerJ Clin Oncol2011292675268221646616
   PubMed Web of Science ®Google Scholar